FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216012020> ?p ?o ?g. }

• W3216012020 endingPage "691" @default.
• W3216012020 startingPage "674" @default.
• W3216012020 abstract "This long-term post-marketing surveillance (SAPPHIRE) collected information on the safety and effectiveness of canagliflozin (approved dose 100 mg) prescribed to patients with type 2 diabetes mellitus (T2DM) in real-world practice in Japan.Patients with T2DM who were prescribed canagliflozin between December 2014 and September 2016 were registered and observed for up to 3 years. Safety was evaluated in terms of adverse drug reactions (ADRs). Effectiveness was assessed in terms of glycaemic control. Data were also analysed across age subgroups (< 65, ≥ 65 to < 75, and ≥ 75 years old) and the estimated glomerular filtration rate (eGFR) categories for chronic kidney disease (G1-G5 based on eGFR) at baseline.A total of 12,227 patients were included in the safety analyses and 11,675 in effectiveness analyses. Overall, 7104 patients were treated with canagliflozin for ≥ 3 years. The mean age, haemoglobin A1c (HbA1c), and eGFR at baseline were 58.4 ± 12.5 years, 8.01 ± 1.49%, and 80.04 ± 21.85 mL/min/1.73 m2, respectively. There were 1836 ADRs in 1312 patients (10.73%) and 268 serious ADRs in 225 patients (1.84%). The most common ADRs were those related to volume depletion (1.39%), genital infection (1.34%), polyuria/pollakiuria (1.23%), and urinary tract infection (1.19%). The frequencies of ADRs tended to increase with age and stage of chronic kidney disease. The reductions in mean HbA1c after starting canagliflozin were maintained for up to 3 years with a mean change of - 0.68% (n = 6345 at 3 years). Maintained reductions in mean HbA1c were observed in each age subgroup and in patients with G1-G3b renal function.This surveillance in real-world clinical practice showed that canagliflozin provides sustained glucose-lowering effects in patients with T2DM, including elderly patients and patients with moderate renal impairment, without new safety concerns beyond those already described in the Japanese package insert.JapicCTI-153048.Canagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose levels by increasing urinary glucose excretion. It was approved for the management of blood glucose levels in patients with type 2 diabetes mellitus following clinical trials. However, clinical trials may not fully represent the safety or effectiveness of a drug in real-world clinical practice. Therefore, a 3-year post-marketing surveillance was performed in Japan to obtain safety and effectiveness data for a large group of 12,227 patients with type 2 diabetes mellitus and various demographic/clinical characteristics. Safety and effectiveness data were collected for up to 3 years while patients were treated with canagliflozin. Adverse drug reactions occurred in 10.73% of patients. The most common types of adverse drug reactions were those related to volume depletion (body fluid decreased), followed by genital infection, polyuria/pollakiuria (increased urination), and urinary tract infection. Adverse drug reactions tended to be more common in elderly patients and in patients with renal impairment. As expected, canagliflozin was associated with improvements in haemoglobin A1c, a marker of blood glucose control, in patients with type 2 diabetes, including in elderly patients and patients with moderate renal impairment. In this surveillance in real-world clinical practice, long-term treatment with canagliflozin raised no new safety concerns beyond the information already included in the Japanese package insert. Canagliflozin provides sustained glucose-lowering effects." @default.
• W3216012020 created "2021-12-06" @default.
• W3216012020 creator A5009587808 @default.
• W3216012020 creator A5036113498 @default.
• W3216012020 creator A5049340312 @default.
• W3216012020 creator A5058512882 @default.
• W3216012020 creator A5059306092 @default.
• W3216012020 creator A5077189198 @default.
• W3216012020 creator A5083876246 @default.
• W3216012020 date "2021-12-02" @default.
• W3216012020 modified "2023-10-06" @default.
• W3216012020 title "Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance" @default.
• W3216012020 cites W1558469318 @default.
• W3216012020 cites W1996042816 @default.
• W3216012020 cites W1999892123 @default.
• W3216012020 cites W2045790951 @default.
• W3216012020 cites W2060263164 @default.
• W3216012020 cites W2087539094 @default.
• W3216012020 cites W2089283085 @default.
• W3216012020 cites W2120655733 @default.
• W3216012020 cites W2121336886 @default.
• W3216012020 cites W2147205430 @default.
• W3216012020 cites W2175616918 @default.
• W3216012020 cites W2434919988 @default.
• W3216012020 cites W2521756482 @default.
• W3216012020 cites W2562563466 @default.
• W3216012020 cites W2586108119 @default.
• W3216012020 cites W2586681261 @default.
• W3216012020 cites W2626446274 @default.
• W3216012020 cites W2626600315 @default.
• W3216012020 cites W2763987852 @default.
• W3216012020 cites W2767087620 @default.
• W3216012020 cites W2768576350 @default.
• W3216012020 cites W2793278118 @default.
• W3216012020 cites W2804715956 @default.
• W3216012020 cites W2884088336 @default.
• W3216012020 cites W2921723272 @default.
• W3216012020 cites W2939222610 @default.
• W3216012020 cites W2965056983 @default.
• W3216012020 cites W2990624103 @default.
• W3216012020 cites W3037131664 @default.
• W3216012020 cites W3073811870 @default.
• W3216012020 cites W3091685727 @default.
• W3216012020 cites W4211025575 @default.
• W3216012020 cites W4230007976 @default.
• W3216012020 cites W4233757680 @default.
• W3216012020 doi "https://doi.org/10.1007/s12325-021-01984-4" @default.
• W3216012020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34853985" @default.
• W3216012020 hasPublicationYear "2021" @default.
• W3216012020 type Work @default.
• W3216012020 sameAs 3216012020 @default.
• W3216012020 citedByCount "7" @default.
• W3216012020 countsByYear W32160120202022 @default.
• W3216012020 countsByYear W32160120202023 @default.
• W3216012020 crossrefType "journal-article" @default.
• W3216012020 hasAuthorship W3216012020A5009587808 @default.
• W3216012020 hasAuthorship W3216012020A5036113498 @default.
• W3216012020 hasAuthorship W3216012020A5049340312 @default.
• W3216012020 hasAuthorship W3216012020A5058512882 @default.
• W3216012020 hasAuthorship W3216012020A5059306092 @default.
• W3216012020 hasAuthorship W3216012020A5077189198 @default.
• W3216012020 hasAuthorship W3216012020A5083876246 @default.
• W3216012020 hasBestOaLocation W32160120201 @default.
• W3216012020 hasConcept C126322002 @default.
• W3216012020 hasConcept C126894567 @default.
• W3216012020 hasConcept C134018914 @default.
• W3216012020 hasConcept C159641895 @default.
• W3216012020 hasConcept C2777451236 @default.
• W3216012020 hasConcept C2778653478 @default.
• W3216012020 hasConcept C2780180277 @default.
• W3216012020 hasConcept C2910068830 @default.
• W3216012020 hasConcept C555293320 @default.
• W3216012020 hasConcept C71924100 @default.
• W3216012020 hasConceptScore W3216012020C126322002 @default.
• W3216012020 hasConceptScore W3216012020C126894567 @default.
• W3216012020 hasConceptScore W3216012020C134018914 @default.
• W3216012020 hasConceptScore W3216012020C159641895 @default.
• W3216012020 hasConceptScore W3216012020C2777451236 @default.
• W3216012020 hasConceptScore W3216012020C2778653478 @default.
• W3216012020 hasConceptScore W3216012020C2780180277 @default.
• W3216012020 hasConceptScore W3216012020C2910068830 @default.
• W3216012020 hasConceptScore W3216012020C555293320 @default.
• W3216012020 hasConceptScore W3216012020C71924100 @default.
• W3216012020 hasFunder F4320321625 @default.
• W3216012020 hasFunder F4320327566 @default.
• W3216012020 hasIssue "1" @default.
• W3216012020 hasLocation W32160120201 @default.
• W3216012020 hasLocation W32160120202 @default.
• W3216012020 hasLocation W32160120203 @default.
• W3216012020 hasOpenAccess W3216012020 @default.
• W3216012020 hasPrimaryLocation W32160120201 @default.
• W3216012020 hasRelatedWork W1633229201 @default.
• W3216012020 hasRelatedWork W1975155164 @default.
• W3216012020 hasRelatedWork W2021055445 @default.
• W3216012020 hasRelatedWork W2105019708 @default.
• W3216012020 hasRelatedWork W2124543160 @default.
• W3216012020 hasRelatedWork W2462691803 @default.
• W3216012020 hasRelatedWork W2808725516 @default.

• next